Arcturus Therapeutics Earnings Reports

Arcturus Therapeutics reported Q4 2024 revenue of $22.8 million, down from $30.9 million in Q4 2023, mainly due to lower milestone achievements from the CSL agreement. The company posted a net loss of $30.0 million compared to $11.7 million in the prior year quarter, with EPS decreasing to -$1.11 from -$0.44. Operating expenses increased to $56.2 million, driven by higher research and development costs.

Arcturus Therapeutics reported its Q3 2024 financial results, featuring a revenue of $41.7 million and a net loss of $6.9 million, or ($0.26) per diluted share. The company achieved a $25 million commercial milestone with the first sale of KOSTAIVE® in Japan and anticipates another milestone related to potential European approval in the first quarter of 2025. The company's cash runway is expected to extend through the first quarter of fiscal year 2027.

Arcturus Therapeutics reported a revenue of $49.9 million for the second quarter of 2024, a significant increase of $39.4 million compared to the same period in 2023. The net loss for the quarter was $17.2 million, or ($0.64) per diluted share, compared to a net loss of $52.6 million, or ($1.98) per diluted share in the second quarter of 2023.